SAN DIEGO, May 13, 2016 /PRNewswire/ -- Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced that results from the clinical investigation of Toca 511 & Toca FC for the treatment of recurrent high grade glioma will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7 in Chicago, and the 17th Biennial Canadian Neuro-Oncology (CNO) Meeting, to be held June 9-11 in Toronto.
In addition, preclinical data demonstrating that Tocagen's investigational therapy induces an anti-tumor immune response will be presented at Immunology 2016™, the Annual Meeting of The American Association of Immunologists (AAI), being held May 13-17 in Seattle.
Details of the ASCO presentation are as follows:
Presentation Type: Poster
Title: Encouraging survival with Toca 511 and Toca FC compared to external lomustine control
Date and Time: Saturday, June 4, 1:00-4:30 p.m. CT
Presenter: Timothy Cloughesy, M.D., director of the University of California, Los Angeles, Neuro-Oncology Program
Details of the CNO presentations are as follows:
Presentation Type: Podium
Title: Cancer-selective gene therapy with Toca 511 and Toca FC for the treatment of recurrent high grade glioma
Date and Time: Friday, June 10, 2:00-3:20 p.m. ET
Presenter: Tom Mikkelsen, M.D., co-director of the Hermelin Brain Tumor Center at Henry Ford Hospital and president and scientific director of the Ontario Brain Institute
Presentation Type: Poster
Title: Toca 5: A phase 2/3 randomized, open-label study of Toca 511, a retroviral replicating vector, combined with Toca FC versus standard of care in patients undergoing planned resection for recurrent glioblastoma (GBM) or anaplastic astrocytoma (AA) (NCT02414165)
Date and Time: Saturday, June 11, 10:00-10:45 a.m. ET
Presenter: Gelareh Zadeh, M.D., Ph.D., associate professor at the Department of Surgery, University of Toronto and Wilkins Family Chair in Brain Tumor Research
Details of the AAI presentation are as follows:
Presentation Type: Poster
Title: Temporal changes in tumor-associated immune cell populations in subcutaneous Tu-2449SC tumors transduced with Toca 511 following treatment with 5-FC
Date and Time: Monday, May 16, 2:30-3:45 p.m. PT
Presenter: Leah Mitchell, Ph.D., research scientist at Tocagen
About Tocagen
Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer from within. The company is developing its lead investigational product candidate, Toca 511 (vocimagene amiretrorepvec) & Toca FC (extended-release 5-fluorocytosine), initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Tocagen has initiated the Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial of Toca 511 & Toca FC in patients with recurrent HGG, which is designed to serve as a potential registrational trial. More information about the clinical trial can be found at www.tocagen.com/toca5. In 2016, Tocagen plans to initiate clinical trials of Toca 511 & Toca FC in patients with newly diagnosed HGG and other solid tumors. Tocagen obtained Fast Track designation from the U.S. Food and Drug Administration, for Toca 511 & Toca FC for the treatment of recurrent HGG and Orphan drug designation for the treatment of glioblastoma (GBM), a subset of HGG. Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information visit www.tocagen.com or follow @Tocagen.
SOURCE Tocagen Inc.